S
ARQT icon

SignatureFD’s Arcutis Biotherapeutics ARQT Stock Holding History

SignatureFD’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56K Sell
2,137
-10
-0.5% -$233 ﹤0.01% 1802
2026
Q1 		$50.6K Hold
2,147
– – ﹤0.01% 1710
2025
Q4 		$62.3K Buy
2,147
+10
+0.5% +$256 ﹤0.01% 1525
2025
Q3 		$40.3K Hold
2,137
– – ﹤0.01% 1754
2025
Q2 		$30K Sell
2,137
-1,413
-40% -$19.8K ﹤0.01% 1873
2025
Q1 		$55.5K Buy
3,550
+55
+2% +$775 ﹤0.01% 1508
2024
Q4 		$48.7K Hold
3,495
– – ﹤0.01% 1602
2024
Q3 		$32.5K Hold
3,495
– – ﹤0.01% 1819
2024
Q2 		$32.5K Sell
3,495
-24
-0.7% -$217 ﹤0.01% 1733
2024
Q1 		$34.9K Buy
+3,519
New +$26.3K ﹤0.01% 1730
2023
Q4 		– Sell
-346
Closed -$1.84K – 3133
2023
Q3 		$1.84K Sell
346
-22
-6% -$187 ﹤0.01% 2793
2023
Q2 		$3.51K Buy
368
+250
+212% +$2.77K ﹤0.01% 2634
2023
Q1 		$1.3K Sell
118
-174
-60% -$2.52K ﹤0.01% 2924
2022
Q4 		$4.32K Sell
292
-44
-13% -$769 ﹤0.01% 2538
2022
Q3 		$6K Sell
336
-49
-13% -$1.11K ﹤0.01% 2309
2022
Q2 		$8K Buy
385
+93
+32% +$1.91K ﹤0.01% 2205
2022
Q1 		$6K Buy
292
+282
+2,820% +$4.77K ﹤0.01% 2379
2021
Q4 		$0 Sell
10
-585
-98% -$11.6K ﹤0.01% 3098
2021
Q3 		$14K Buy
+595
New +$13.6K ﹤0.01% 1897

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SignatureFD's ARQT Position: Q2 2026 in Review

SignatureFD reduced its Arcutis Biotherapeutics (ARQT) stake by 0.47% in Q2 2026, selling an estimated $233 and leaving 2,137 shares worth $56K. The position accounts for ﹤0.01% of the portfolio, ranked #1802.

SignatureFD first reported a position in ARQT in Q3 2021 and has held it in 19 quarters since. The position peaked at $62.3K in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • SignatureFD held 2,137 shares of Arcutis Biotherapeutics worth $56K as of Q2 2026.
  • SignatureFD sold 10 Arcutis Biotherapeutics shares in Q2 2026, an estimated $233.
  • Arcutis Biotherapeutics made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #1802 holding.
  • SignatureFD first reported a position in Arcutis Biotherapeutics in Q3 2021 and has held it in 19 quarters since.
  • SignatureFD's Arcutis Biotherapeutics position peaked at $62.3K in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.